W. Fraser Symmans
The University of Texas MD Anderson Cancer Center · 1,183 works · 55,029 citations · h-index 110
Top works
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
- Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
- Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
- Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- An International Ki67 Reproducibility Study
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
- Adaptive Randomization of Neratinib in Early Breast Cancer
- Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
- SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer